Search research articles
Contact Us
Filters
Showing results (21-30 of 33) with videos related to
Page
of 4
Sort By:
Theranostics
|
February 28, 2019
MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma
Filippo Rossignoli, Carlotta Spano, Giulia Grisendi, et al.
Cancers
|
July 24, 2019
<i>ANGPT2</i> and <i>NOS3</i> Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
Giorgia Marisi, Elisabetta Petracci, Francesco Raimondi, et al.
Scientific Reports
|
February 12, 2019
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer
Carlotta Spano, Giulia Grisendi, Giulia Golinelli, et al.
NPJ Precision Oncology
|
February 1, 2024
Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma
Chiara Chiavelli, Malvina Prapa, Giulia Rovesti, et al.
Gastrointestinal Tumors
|
November 27, 2019
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience
Giulia Rovesti, Giulia Orsi, Andrikou Kalliopi, et al.
Tumori
|
November 27, 2020
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus
Andrea Pretta, Pina Ziranu, Marco Puzzoni, et al.
Gastrointestinal Tumors
|
November 27, 2019
Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort
Andrea Casadei-Gardini, Leonardo Solaini, Laura Riggi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 7, 2020
Association of <i>NOS3</i> and <i>ANGPT2</i> Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study
Andrea Casadei-Gardini, Giorgia Marisi, Vincenzo Dadduzio, et al.
Targeted Oncology
|
October 28, 2020
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma
Giulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, et al.
Targeted Oncology
|
October 12, 2020
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma
Giulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 33) with videos related to
Sort By:
Page
of 4
Theranostics
|
February 28, 2019
MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma
Filippo Rossignoli, Carlotta Spano, Giulia Grisendi, et al.
Cancers
|
July 24, 2019
<i>ANGPT2</i> and <i>NOS3</i> Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
Giorgia Marisi, Elisabetta Petracci, Francesco Raimondi, et al.
Scientific Reports
|
February 12, 2019
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer
Carlotta Spano, Giulia Grisendi, Giulia Golinelli, et al.
NPJ Precision Oncology
|
February 1, 2024
Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma
Chiara Chiavelli, Malvina Prapa, Giulia Rovesti, et al.
Gastrointestinal Tumors
|
November 27, 2019
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience
Giulia Rovesti, Giulia Orsi, Andrikou Kalliopi, et al.
Tumori
|
November 27, 2020
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus
Andrea Pretta, Pina Ziranu, Marco Puzzoni, et al.
Gastrointestinal Tumors
|
November 27, 2019
Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort
Andrea Casadei-Gardini, Leonardo Solaini, Laura Riggi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 7, 2020
Association of <i>NOS3</i> and <i>ANGPT2</i> Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study
Andrea Casadei-Gardini, Giorgia Marisi, Vincenzo Dadduzio, et al.
Targeted Oncology
|
October 28, 2020
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma
Giulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, et al.
Targeted Oncology
|
October 12, 2020
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma
Giulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, et al.
Page
of 4